CA
NZ
UK
AU
IND
US
● Milestone payments could reach about $134 million.
● It has shipped over 8 million microinverters from US facilities.
Key Highlights● Eupraxia climbed on November 9 after RBC initiated coverage.● The rating is Outperform with a $14 price target.● The shares rose to about $6.89.● An interim EP-104GI readout is expected in December.A bullish first lookEupraxia Pharmaceuticals (NASDAQ:EPRX) climbed on Monday, November 9, …
● Shares were up by a double-digit amount at $23.18.
● Fervo highlighted a 396-megawatt power deal with Google.
● The regimen shrank tumors in about one in three assessable patients.
● The cash offer is a premium of nearly two-fifths.
● Falling oil prices and an AI rebound tied the group's rally.
● The restatement covers the 2025 Form 10-K and first and second quarter 2026 reports.
● The company is evaluating strategic initiatives.
Please wait processing your request...